RCUS•benzinga•
Goldman Sachs Maintains Neutral on Arcus Biosciences, Lowers Price Target to $13
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 8, 2025 by benzinga